Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $24.50 Average Price Target from Analysts

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) have earned an average rating of “Hold” from the ten research firms that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $24.50.

A number of equities research analysts recently weighed in on PCRX shares. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $18.00 price target on shares of Pacira BioSciences in a report on Tuesday, January 14th. Needham & Company LLC upped their target price on shares of Pacira BioSciences from $22.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Barclays cut their price target on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 12th. HC Wainwright restated a “buy” rating and set a $39.00 price objective on shares of Pacira BioSciences in a report on Wednesday, December 4th. Finally, Jefferies Financial Group increased their target price on shares of Pacira BioSciences from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th.

Pacira BioSciences Stock Up 2.1 %

NASDAQ PCRX opened at $22.84 on Friday. The firm has a 50-day simple moving average of $18.80 and a 200 day simple moving average of $17.45. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The stock has a market cap of $1.05 billion, a PE ratio of -11.25 and a beta of 0.76. Pacira BioSciences has a twelve month low of $11.16 and a twelve month high of $34.01.

Institutional Trading of Pacira BioSciences

A number of hedge funds have recently made changes to their positions in PCRX. Nisa Investment Advisors LLC raised its holdings in Pacira BioSciences by 495.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $62,000 after buying an additional 2,749 shares during the last quarter. CWM LLC grew its stake in shares of Pacira BioSciences by 713.6% in the third quarter. CWM LLC now owns 6,517 shares of the company’s stock worth $98,000 after purchasing an additional 5,716 shares during the last quarter. Virtus Investment Advisers Inc. bought a new stake in shares of Pacira BioSciences in the third quarter worth $98,000. China Universal Asset Management Co. Ltd. increased its holdings in Pacira BioSciences by 62.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,872 shares of the company’s stock valued at $134,000 after purchasing an additional 3,404 shares during the period. Finally, Canada Pension Plan Investment Board bought a new position in Pacira BioSciences during the 2nd quarter worth $140,000. 99.73% of the stock is owned by institutional investors and hedge funds.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.